Press Releases

  • || Catamaran Bio Announces Appointment of Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing

    Catamaran Bio, Inc., a biotechnology company developing off-the-shelf CAR-NK cell therapies to treat cancer, today announced the appointment of Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing. Dr. Gold is a recognized leader with more than 25 years of experience in cell and gene therapy process development and GMP manufacturing.

      Full Press Release
  • || Catamaran Bio and Bio-Techne Announce Expanded Collaboration for CAR NK Cell Manufacturing Technologies

    Broadened agreement includes the development of novel technologies for allogeneic CAR-NK cell expansionCatamaran also secures broad worldwide license to TcBuster™ transposon system for clinical and commercial manufacturing of next generation cell therapies.

      Full Press Release
  • || Catamaran Bio’s Scientific Founder Leads Pivotal Advancements in Non-viral Engineering of CAR-NK Cells Using Novel Transposon Technology

    Transposon technology efficiently generates active CAR-NK cells and has potential advantages compared to viral approaches. Oral presentation highlighted at the American Society of Gene and Cell Therapy annual meeting

      Full Press Release
  • || Catamaran Bio Announces Appointment of Scott Holmes as Chief Financial Officer

    Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat patients with significant unmet medical need, today announced the appointment of Scott Holmes, MS, MBA, as Chief Financial Officer.

      Full Press Release
  • || Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer

    CAMBRIDGE, Mass. – February 4, 2021 – Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat diseases with significant unmet medical need, today announced the appointment of Alvin Shih, MD, MBA, as President and Chief Executive Officer. He has concurrently been appointed to the Board of Directors for Catamaran. Dr. Shih […]

      Full Press Release
  • || Catamaran Bio Launches with $42 Million Financing to Develop Off the Shelf CAR-NK Cell Therapies to Treat Solid Tumors

    Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, today announced that the company has launched with $42 million in financing.

      Full Press Release